Biomarkers of LRRK2 and lysosomal dysfunction in Progressive Supranuclear Palsy
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Common and rare genetic variants in LRRK2 have been linked with sporadic and familial Parkinson’s disease (PD). Recently, we discovered that common genetic variation near the LRRK2 locus determined survival in progressive supranuclear palsy (PSP). Our study aimed to explore biomarkers of LRRK2 and lysosomal dysfunction in PSP.
Methods
Immunoblotting was used to measure total LRRK2 and LRRK2-dependent Rab10 phosphorylation at Threonine73 (pRab10 Thr73 ) in neutrophil and monocyte samples from PSP and control participants. Urine samples were applied to a multiplexed assay to quantitate bis(monoacylglycerol)phosphate (BMP) species as markers of lysosomal dysfunction. CSF samples from a wider cohort of PSP and control participants were applied to a stable isotope standards and capture by anti-peptide antibodies assay to measure total LRRK2 and pRab10 Thr73 levels. LRRK2 genotypes (rs76904798 and rs2242367) and 1-year change in PSP rating scale scores were obtained.
Results
61 PSP and 34 control participants were included. Total urine 22:6-BMP levels were higher in PSP vs. control samples (p=0.04) and correlated with CSF total LRRK2 levels (r=0.49, p=0.04). In PSP, carriers of the alternate allele (CT and TT genotypes) at the LRRK2 PD risk variant, rs76904798, had higher levels of CSF total LRRK2 vs. CC genotype (p=0.02). A similar but non-significant trend was observed for the LRRK2 PSP survival variant, rs2242367 (p=0.08). Baseline monocyte total LRRK2 levels predicted 1-year change in the PSP rating scale score (p=0.008).
Conclusions
Biochemically defined lysosomal dysfunction is evident in PSP. Genetic and biochemical stratification may identify PSP patients that would benefit from LRRK2-targetting therapies.
